This is an amended filing · View original →
Chong Kun Dang Pharmaceutical Corp. Q3 profit from main business KRW 22.0 billion, up 5.1% from a year earlier
AI summary · Not investment advice
Chong Kun Dang sold KRW 434.3 billion in Q3 and earned KRW 22.0 billion from its main business, up 5.1% from a year earlier and 18.5% from the prior quarter.
Operating profit · 3 months
KRW 22.0 billion
Key facts
- Revenue (3 months)
- KRW 434.3 billion
- Net income (3 months)
- KRW 19.3 billion
- Period
- Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
- Revenue (prior-year 3 months)
- KRW 429.8 billion
- Revenue (year to date)
- KRW 1.4 trillion
- Operating profit (prior-year 3 months)
- KRW 21.0 billion
- Operating profit (year to date)
- KRW 54.7 billion
- Net income (prior-year 3 months)
- KRW 20.2 billion
- Net income (year to date)
- KRW 52.4 billion
Commentary
AI commentary · Not investment advice
What happened
Chong Kun Dang filed its quarterly report with consolidated results for the third quarter. Sales for the latest 3 months were KRW 434.28 billion. That is 1.0% above the same 3 months a year earlier and 9.2% below the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the latest 3 months was KRW 22.05 billion. It rose 5.1% from a year earlier and 18.5% from the previous quarter. Net income (the final profit after taxes and other costs) was KRW 19.32 billion. It fell 4.5% from a year earlier and 5.4% from the previous quarter.
What changes for shareholders
For the year to date, from January 1 to September 30, sales were KRW 1,360.51 billion. Operating profit was KRW 54.75 billion. Net income was KRW 52.36 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
C